AMRX Biotech earnings Today LONGAMRX is a penny biotechnology stock with earnings out on the Friday the 4th.
As you can see on the 15 minute chart, it took off out of consolidation on
Wednesday afternoon in a burst of price volume and volatility into an
ascending parallel channel.
I will buy the stock in the pre-market attempting to exploit the momentum
going into earnings. If there is a miss, I will quickly liquidate and instead
buy put options expiring on 8/18 striking $ 5 and get as many as 100 of
them. This will be a highly risky trade albeit with a comparable reward.
I will position to 0.05% of my account cash balance and no more.
Biotechnology
LABU is about to rally hard before a massive crashLABU is gearing up for a massive rally before it dumps. I have seen this chart pattern alot and I am looking forward to see how it plays out.
Not investment advice, please do your DD.
FLMD biotechology rising post earningsFLMD had earnings in May with positive earnings beating the expectation of analysts that
it would continue to lose quarter after quarter. Investors and traders have reacted with a
80% run-up in the month after those earnings. On the 30-minute chart besides the consistent
uptrend with minor corrections, what stands out for me is the increasing volumes relative
to volumes before the last earnings report. Off the chart, I find information that insider trading
with buying more shares on top of existing holdings leads me to believe that this company
expects increasing revenues and sustained earnings.
EBS a biotech company focused on vaccinesEBS is a small biotechnology company whose forte is the clean processing and manufacturing
facility that the FDA requires for certain bioprocessing to be certified for delivery of products
to end-user patients. It is not a research facility like the one in China that accidentally released
COVID and the global impact will be likely felt for another decade. EBS does depend on
federal support and income from contract work from vaccine manufacturers. There is
reasonable expectation or persistent and consistent revenues ongoing without fail unless
the FDA decertified the facilities. On the chart, EBS is in a flat bottom triangle on its base.
It is presently rising out of the triangle and towards the mean anchored VWAP It is just above
The POC line which functions as dynamic support in the demand zone. I see a long trade
with the stop loss below the POC line, the first target the blue line representing one standard
deviation above the mean VWAP at about 9.4 while the second target is the redline two
standard deviations above the mean VWAP at about 10.05 while the final target contemplates
that EBS will challenge the high in May of 10.75.
FULC Biotech Fib Level BouncdFULC on the 15 minute chart had a good response to favorable earnings and then retraced.
It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume
profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling
volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10% price
rise in the after-hours which is typically a busy trading period for biotechnology penny stocks.
I will take a long trade on FULC in after hours and take off a part of the position in the next
trading day and hold the rest through the weekend.
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked)
approximately a doubling of the shart price in the next year. Like many low share priced
biotechnology stocks the price is based on perceived future earnings which can be affected
by favorable FDA process, or well-received research at industry conferences and changing
financials within the company. In general, they have a low beta meaning these stocks are not
general market responsive and run on their own present or future merits.
On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal
into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two
days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green.
I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days
for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology
trades long with a high R:R due to the inheret risk level.
VRPX Biotechnology Penny Stock Post EarningsVRPX was on a downtrend from mid-February into a reversal the beginning of May. VRPX
beat earnings up still has no cash flow which is very common in this subsector. VRPX is priced
on the potential of future earnings. The short and long-moving averages ratio shows bullish
momentum also shows strength with an upper Bollinger Band "walk". Price has climbed over
the POC line so it is higher than the mean of the share price traded for the duration of the
volume profile. I see this as a risky long setup expectant of a 40% profit based on the target
of the YTD high in February.
BLUE Biotechnology New Earnings Catalyst LONGBlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time
but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks
since earnings which is about 500% annualized. GO BLUE.
On the daily chart, price was above VWAP and consolidating much of last fall then dropped
this YTD until the earnings report of last week. An uptrend is seen after the earnings.
This has been a significant reversal sustained over the past month
with price rising above the support / demand zone below it. At present, price is one
standard deviation below VWAP making it undervalued and ascending.
I see this as a risky long trade like many biotechology penny stocks but with a decent
probability of profit in consideration of a target of 6.15 which is the top of the long
term high volume area. the stop loss is just below the POC line of the volume profile
at 3.15 An entry at 4.62 ( limit order above SMA200 (redlne) would yield at profit of
1.50 with a risk of 0.48 making for a R:R of 3:1. Another earnings report is coming up this
week. If it is favorable, BLUE could go parabolic to hit the target in a day or two.
If not, it will be time to exit the trade.
$XBI ETF Biotechnology Bull FlagOn 4/11/23 our Algo alert software had a buy signal, today there is a really nice bull flag forming on the AMEX:XBI ETF Biotechnology sector
IMGN Biotech Post Earnings IMGN had great earnings the last days of April and has been trending up ever since.
It is riding the upper Bollinger band consistently in this past wee. The volume spike
after earnings has subsided but ongoing volume is at about 5X the moving average of
early April and March. Increased volume supports price momentum. The volume spike
here is obvious and significant.
IMGN announced a public offering. I see this as a positive. It is primed for increasing
growth but needs the fuel. Interest rates are high. Stock offering will raise cash
and all shareholders will be rewarded. IMGN is resting and consolidated in a narrow
range during this public offering. See also the favorable article from IBD linked below.
I see IMGN as a solid swing long until the next earnings. I will watch for an uncoiling
upon completion of the offering with resumption of momentum moving forward.
LABU Triple Leveraged Biotech Sector ETFOn the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity.
On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving
the bullish momentum. Small-cap speculative biotech companies are in a growth mode right now no matter adverse economic conditions
for those yet to have any earnings. Big pharma is more concerned about federal attempts to further regulate prices than the economy.
On the volume profile, price has ascended to above the high volume trading area on the strength of buyer interest propelling the
momentum. Overall, this looks to be a decent long trade. The target is $ 9.00 the YTD high back in February.
MGRX Biotechonolgy IPO LONGMGRX a recent IPO produces a med for erectile dysfunction without FDA approval;
They are basically selling a generic version of an approved medication and bypassing
the patent protections and betting they will fly under the regulator radar apparatus.
As might be expeted this recent nano-IPO is highlly volatile. Play with it only
if you have the requisite skills to do so and only with risk capital.
it does the marketing through direct to consumer telehealth services.
>>>>>>>>>>>>>>>>>>See also the link below <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
On review and analysis on the 30 minute chart, the price action is squeezing
down in a flat bottom triangle likely setting up a breakout upside.
The RSI oscillator shows RSI crossing 50% from below.
Volatility is compressing down inside the triangle for a squeeze set up.
Targets are based on the supply and demand zones of the Luxalgo indicator.
The first parget is the midline between the zones while the final target
is just below the supply zone. As can be seen on the chart, the first target
is about 100% upside while the final target is 200% upside. One of the
position is closed at each target making the return 150% overall.
Stop loss is below the demand zone. A stop loss is 15% yields an overall
reward to risk ration of 10:1.
APLT Biotech NASDAQ Penny LONGApplied Therapeutics is an uptrending biotechnology company that has earnings
in prior quarters and is heading into another earnings report about may 11th.
The run up in price cction is largely on the proposition of future growth much
like TSLA back in the day.
On the chart besides the obvious uptrend, the volume indicator shows a dramatic
volume surge compared with the running 50 day average while the MACD shows
the lines above the histogram and running upward and parallel.
The ideal entry would be a pullback as the price is now quite extended however
I do not believe that will occur until at least after earnings. I believe
this strong runner will continue until earnings unabated.
As a penny stock many shares can be taken and then the position can be closed
in partials along the way thus taking profits and decreasing the risk in steps.
The same applies to the call options.
PFE Large Cap Pharma increased its dividendPFE just raised its dividend On the chart it has been trending downward
as shown also by a down sloping anchored VWAP bands. Price is currently
sitting at long term support and two standard deviations below VWAP.
It appears to be ready to reverse from the deep undervalued area.
In confirmation, teh voume indicator shows moderate increased relative
volume compared with March. I see this as a good opportunity to enter
a swing long trade or investment. PFE has its increased dividend as a
hint to shareholders of increasing earnings also with the next generation of
COVID vaccines in the pipeline along with a diversified line of other
products. The only thing that will slow PFE down in federal legislation to
limit the retail MSRP prices of its products to all consumers including those
with no insurance and commercial coverage outside federal programs.
PFE is solid as a rock. I see the buy signal.
TNYA Biotechology Penny NASDAQ LONGTNYA has been in consolidation the past two days being in the flag of
a bull flag pattern on the 1H chart. Earnings about six weeks ago were
solid especially for a biotechnology stock which are generally priced
based on future potential and not current performance.
( Fundamentally TNYA is in the gene splicing /slicing place which is
perhaps the most lucrative and therapeutic of all of the various
areas in the biotechnology realm. Seemingly, its potential is
expodentially high. )
The zero lag MACD lines have crossed under the histogram which in
general can be considered as a buy signal. The histogram has flipped to
positive.
Upside to the overhead resistance zone by the Luxalgo indicator
is from an entry of about 5 to 6 or about 20%.
Very recent high relative volume as compared with
the 50 day moving average further supports a long trade at this
time. The stop loss would be $.02 below the POC line of the
volume profile.
I will play this with options to further leverage the price action.
Both options and stock are inexpensive for a small account.
MGRX Biotech Penny Stock Pullback for Continuation LONGMGRX with some FDA news catalyst got a lot of action on the last session of the week.
With the pullback and overwhelming volume during the session, a continuation into
the upcoming week is entirely reasonable. ( see also the link)
MGRX had a last price of about $1.50 about a 50% retracement from the high of the day.
I will take a position at market price in the pre-market opening the week. The
target will be $2.25 or midway between the current price and the high of the last session.
This will represent a 50% Return on Trading Position. I will set a stop loss at $ 1.40
representing a 10% loss. Price at present is sitting on a confluence of support of
both the 20 and 50 HMAs along with the lowermost VWAP band. The reward for risk is 5X.
MGRX does not have options. I expect the long trade to hit the continuation target
in less than 5 days. I will set a buy-stop order to take a position when the price exceeds
$ 1.55 with a stop loss of $0.15 to account for the expected volatility.
$CABA Righty Tighty- Massive move 2,000%+
- Obeyed 20 MA for entire move
- Sitting back on 20 MA
- High ADR
- Tight right side
- Biotech
ACHV a Biotech company after earningsACHV on the 4H seems to be demonstrating a "High Bull Flag Pattern"
after a big uptrend to start the year. Earnings on Thursday 3/16 were
quite favorable.On the relative volume indicator Friday, May 17th
showed a paradoxical huge selling volume spike to finish out this week.
( I mislabelled this as upcoming on the chart)
Paradoxically, the last earnings report in November was poor but
resulted in strong upward price action.
The MACD histogram is at the zero line.
Will ACHV resume the uptrend after earnings? Was the selling volume
an institutional trader fake out to set up a lower price to buy call options?
According to Tip Ranks, the analysts give ACHV a high rating with significant
upside. See the link below Who knows but this may be worth watching for signs of
buying volume and accumulation to fuel bullish momentum.
NVAX - Novavax Biotech Short or not?NVAX as seen on the weekly chart has been in price distress for a long time.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take years
( the days of emergency approvals for COVID and related are over)
It would seem that a rich uncle like Moderna ( MRNA) would codcme
around with a take-over offer that could send shares into a moonshot
to back when NVAX thrived before its 95% price decline in the past two
years. This seems to be a great short swing play until more products come
to market or a take-over is announced. This is affirmed by the MACD
histogram being persistently negative for the long-term.
PLSE Earnings Play Long Biotech Pulse Biosciences broke out today from a positive earnings report.
Biotechnology stocks often burn cash on a slow growth cycle.
This company is making money and so the expected reaction occurred.
The volume indicator shows selling pressure in the lead-up to today's earnings.
After the report, the reversal to buying pressure occurred nearly immediately.
The MACD lines crossed under the histogram and then quickly reached
the horizontal zero line serving as a confirmation.
I expect a good follow-through next week. This may be a great penny stock
to trade or even invest.
Bayer AG (BAYN.de) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the German company Bayer AG (BAYN.de). Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 60.750 EUR. According to experts, your stop-loss order should be placed at 54.890 EUR if you decide to enter this position.
Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters.
Sebastian Guth, president of Bayer's pharmaceuticals business in the Americas, in an interview with Reuters, said the company increased U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years and plans to expand on that by another 75% by 2030.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
